Xencor Licenses Xtend Antibody Half-life Prolongation Platform to Merck & Co., Inc. Monrovia, CA March 23, 2009 Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a licensing transaction with Merck & Co., Inc.
Monrovia, CA March 2, 2009. Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies.
Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA February 23, 2009 Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.
Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology Monrovia, Calif. – December 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th
Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference Monrovia, Calif. – December 2, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485
Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO Monrovia, Calif. – June 1, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it will present new data from pre-clinical studies evaluating XmAb®5574, an Fc engineered monoclonal
Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR Monrovia, Calif. – April 15, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research
Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Monrovia, Calif. – April 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical CD19 program for lymphoma and leukemias at the Annual Meeting of the
Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors Monrovia, CA — March 19, 2008 — Xencor, Inc., a company developing protein and antibody therapeutics, today announced that it appointed David R. King as Chairman of its Board of Directors. To Xencor, Mr.